Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug ConjugateKevin J. Hamblett, Joseph A. Francisco, Anastasia K. Kopcha et al.|Clinical Cancer Research|2004Cited by 1.2k
Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody DisulfidesMichael Sun, Stephen C. Alley, Kevin S. Beam et al.|Bioconjugate Chemistry|2005Cited by 365
SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the CytoplasmKevin J. Hamblett, William C. Fanslow, Allison P. Jacob et al.|Cancer Research|2015Cited by 135
AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing GlioblastomaKevin J. Hamblett, William C. Fanslow, Carl J. Kozlosky et al.|Molecular Cancer Therapeutics|2015Cited by 99